X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sterling Biotech with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs GSK PHARMA - Comparison Results

STERLING BIOTECH    Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH GSK PHARMA STERLING BIOTECH/
GSK PHARMA
 
P/E (TTM) x -0.4 53.5 - View Chart
P/BV x 0.0 10.6 0.1% View Chart
Dividend Yield % 0.0 2.7 -  

Financials

 STERLING BIOTECH   GSK PHARMA
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
GSK PHARMA
Mar-18
STERLING BIOTECH/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs112,760 0.4%   
Low Rs32,040 0.2%   
Sales per share (Unadj.) Rs26.8339.0 7.9%  
Earnings per share (Unadj.) Rs-15.041.4 -36.1%  
Cash flow per share (Unadj.) Rs-5.545.9 -11.9%  
Dividends per share (Unadj.) Rs035.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs54.9242.9 22.6%  
Shares outstanding (eoy) m267.8784.70 316.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.37.1 3.7%   
Avg P/E ratio x-0.557.9 -0.8%  
P/CF ratio (eoy) x-1.352.3 -2.4%  
Price / Book Value ratio x0.19.9 1.3%  
Dividend payout %084.5 0.0%   
Avg Mkt Cap Rs m1,862203,280 0.9%   
No. of employees `0001.4NA-   
Total wages/salary Rs m5475,234 10.4%   
Avg. sales/employee Rs Th5,303.3NM-  
Avg. wages/employee Rs Th403.8NM-  
Avg. net profit/employee Rs Th-2,959.0NM-  
INCOME DATA
Net Sales Rs m7,18128,715 25.0%  
Other income Rs m43545 7.8%   
Total revenues Rs m7,22329,260 24.7%   
Gross profit Rs m9475,059 18.7%  
Depreciation Rs m2,543380 669.3%   
Interest Rs m4,3772 218,855.0%   
Profit before tax Rs m-5,9315,222 -113.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0178 0.0%   
Tax Rs m-1,9241,892 -101.7%   
Profit after tax Rs m-4,0073,508 -114.2%  
Gross profit margin %13.217.6 74.9%  
Effective tax rate %32.436.2 89.6%   
Net profit margin %-55.812.2 -456.7%  
BALANCE SHEET DATA
Current assets Rs m14,33521,815 65.7%   
Current liabilities Rs m49,80915,999 311.3%   
Net working cap to sales %-494.020.3 -2,439.0%  
Current ratio x0.31.4 21.1%  
Inventory Days Days40364 634.4%  
Debtors Days Days17119 913.2%  
Net fixed assets Rs m55,43212,475 444.4%   
Share capital Rs m268847 31.6%   
"Free" reserves Rs m13,93519,726 70.6%   
Net worth Rs m14,70120,573 71.5%   
Long term debt Rs m9,4786 157,964.2%   
Total assets Rs m73,98839,475 187.4%  
Interest coverage x-0.42,612.0 -0.0%   
Debt to equity ratio x0.60 221,059.1%  
Sales to assets ratio x0.10.7 13.3%   
Return on assets %0.58.9 5.6%  
Return on equity %-27.317.1 -159.8%  
Return on capital %-6.426.2 -24.5%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,860564 329.8%   
Fx outflow Rs m257,429 0.3%   
Net fx Rs m1,835-6,865 -26.7%   
CASH FLOW
From Operations Rs m1,7194,728 36.4%  
From Investments Rs m-3,148-1,042 302.2%  
From Financial Activity Rs m1,426-3,066 -46.5%  
Net Cashflow Rs m-3620 -0.5%  

Share Holding

Indian Promoters % 33.9 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 0.0 10.2 -  
FIIs % 9.9 23.8 41.6%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 15.4 255.2%  
Shareholders   21,482 102,036 21.1%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   PIRAMAL ENTERPRISES  ABBOTT INDIA  PANACEA BIOTECH  MERCK  NOVARTIS  

Compare STERLING BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 324 Points Lower; Metal and Telecom Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their trading session on a negative note.

Related Views on News

GSK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 26.0% (Quarterly Result Update)

Feb 5, 2019 | Updated on Feb 5, 2019

For the quarter ended December 2018, GSK PHARMA has posted a net profit of Rs 1 bn (up 26.0% YoY). Sales on the other hand came in at Rs 8 bn (up 17.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)

Jul 26, 2018 | Updated on Jul 26, 2018

For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.4% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 6.4% YoY). Sales on the other hand came in at Rs 7 bn (down 4.5% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

More Views on News

Most Popular

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

My Master Series on How to Trade Election 2019(Profit Hunter)

Apr 16, 2019

For 30 years he has watched how elections impact the markets, and practiced how to profit from it. Now he is here...telling you everything. Read on...

Election Series: Follow the World's Biggest Traders To See Where the Money Flows(The 5 Minute Wrapup)

Apr 17, 2019

20% of all the traders bring in 80% of the money. Watch these 20% and you get a working idea of which way the wind is blowing.

A Letter to You from India's No. 1 Trader(The 5 Minute Wrapup)

Apr 15, 2019

It's our great pleasure to introduce Vijay Bhambwani to our readers - we consider Vijay to be India's best trader. Read on to find out why...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 8-QTR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS